Lenalidomida Olainfarm

Lenalidomide, the active ingredient in Lenalidomida Olainfarm, is an immunomodulatory agent presented as an oral tablet for systemic use. It is indicated for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes bearing a del(5q) abnormality, and mantle cell lymphoma, providing anti‑proliferative and anti‑angiogenic effects. The drug’s mechanism involves binding to cereblon, leading to degradation of transcription factors that drive malignant cell growth.

GNH USA supplies Lenalidomida Olainfarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide, ensuring quality, regulatory conformity, and reliable logistics for global distribution.

Lenalidomide is used in hematologic malignancies and related blood disorders.

Multiple Myeloma: improves disease control and prolongs survival in adult patients with relapsed or refractory disease. Myelodysplastic Syndromes: reduces transfusion dependence and improves blood counts in patients with del(5q) cytogenetic abnormality. Mantle Cell Lymphoma: provides disease control in adult patients with relapsed or refractory mantle cell lymphoma.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Neutropenia: decreased neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Nausea: upset stomach often occurring after dosing. - Rash: skin irritation or mild eruptions.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Secondary primary malignancies: emergence of new cancers. - Hepatic failure: significant liver enzyme elevation or dysfunction. - Severe infections: opportunistic or life‑threatening bacterial, viral, or fungal infections. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating Lenalidomida Olainfarm, clinicians should consider several safety measures.

Pregnancy: contraindicated due to teratogenic risk; ensure effective contraception. Breastfeeding: not recommended; advise discontinuation of nursing. Monitor blood counts: perform regular CBC to detect neutropenia or thrombocytopenia. Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. Adjust dose in renal impairment: evaluate renal function and modify dosing accordingly. Store at ambient temperature: keep below 25°C, protect from moisture and direct sunlight.

Lenalidomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lenalidomide exposure. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce therapeutic levels. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - P‑gp inhibitors (e.g., verapamil): may modestly raise plasma concentrations. - NSAIDs: may add to thrombotic risk when combined with lenalidomide.